EUVIMEDEUVIMED entdecken
Open Access

Assessing time-trend bias in glioblastoma prognosis over 2 decades of clinical trials

Giacomo Sferruzza iD, Karthik Desingu, Andrés Cubero Cruz, Gaetano Finocchiaro iD

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noaf158 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Giacomo Sferruzza und 3 weiteren Autor:innen. Beteiligte Einrichtung: Vita-Salute San Raffaele University, Milan, Italy. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The time-trend bias represents a potential limitation in the use of external controls in glioblastoma (GBM) trials. In this study, we assessed whether outcomes for newly diagnosed GBM (ndGBM) patients treated with the standard Stupp protocol in clinical trials have changed over the past 2 decades.

Methods

We retrieved individual patient-survival pseudo-data from Stupp-protocol arms reported in trials published over the last 20 years. Survival distributions were approximated using Weibull distributions, and an Accelerated Failure Time model was used to evaluate any potential time-trend by correcting for identified key prognostic factors.

Results

MGMT methylation status and Karnofsky Performance Status emerged as the main determinants of survival differences among clinical trials. Both in a multivariable regression that included all candidate prognostic factors and after adjustment for the main determinants, the publication year showed no impact on the outcome of the Stupp-protocol control arms. The performance of the model was validated using 3 independent Phase III cohorts, providing additional evidence for the absence of time-trend bias.

Conclusions

No evidence of time-trend bias was observed in Phase III GBM trials over the past 2 decades once major prognostic factors were accounted for.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansPrognosisMaleFemaleClinical Trials as TopicSurvival RateClinical Trials, Phase III as TopicMiddle AgedBiasTime FactorsDNA Modification Methylases

Stichwörter der Autor:innen

Stupp protocolglioblastomahistorical controlstime-trend bias

Substanzen

DNA Modification Methylases

Autor:innen und Institutionen

  • Vita-Salute San Raffaele University, Milan, Italy.
  • Department of Biomedical Engineering, Yale University, New Haven, Connecticut, USA.
  • Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.

ORCID-Profile: Giacomo Sferruzza, Gaetano Finocchiaro

Zitieren

APA

Sferruzza, G., Desingu, K., Cubero Cruz, A., & Finocchiaro, G. (2025). Assessing time-trend bias in glioblastoma prognosis over 2 decades of clinical trials. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf158

Vancouver

Sferruzza G, Desingu K, Cubero Cruz A, Finocchiaro G. Assessing time-trend bias in glioblastoma prognosis over 2 decades of clinical trials. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf158

BibTeX
@article{Sferruzza2025,
  author = {Sferruzza, Giacomo and Desingu, Karthik and Cubero Cruz, Andrés and Finocchiaro, Gaetano},
  title = {Assessing time-trend bias in glioblastoma prognosis over 2 decades of clinical trials},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noaf158}
}
Kostenlos starten →